# Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

> **NCT03711305** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 462 (actual)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer

## Interventions

- **DRUG:** SHR-1316
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03711305
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-30
- **Primary completion:** 2022-10
- **Final completion:** 2023-12
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2022-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03711305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03711305, "Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03711305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*